about
Arginine deprivation therapy for malignant melanomaThe cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeletonAnthrax toxins induce shock in rats by depressed cardiac ventricular functionDistinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation.Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanismsActivity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.Thrombotic thrombocytopenic purpura: prolonged coma with recovery of neurologic function with intensive plasma exchange.Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancerTargeted toxins.Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials.Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia.Immunotherapy of acute myeloid leukemia.Chimeric fusion proteins--diphtheria toxin-based.Cardiac-specific catalase overexpression rescues anthrax lethal toxin-induced cardiac contractile dysfunction: role of oxidative stress and autophagy.Characterization of immunotoxins active against ovarian cancer cell lines.Peptide toxins directed at the matrix dissolution systems of cancer cells.Diphtheria fusion protein therapy of chemoresistant malignancies.Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.Anthrax fusion protein therapy of cancer.Nucleotide sequences in mouse DNA and RNA specific for Moloney sarcoma virus.DAB389EGF fusion protein therapy of refractory glioblastoma multiforme.Diphtheria toxin conjugate therapy of cancer.DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia.Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.Immunotoxin therapy of hematologic malignancies.Novel protein targeted therapy of metastatic melanoma.Induction of apoptosis by tumor cell-targeted toxins.Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Recombinant human arginase toxicity in mice is reduced by citrulline supplementationDissecting the urokinase activation pathway using urokinase-activated anthrax toxin.Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).Human prostate specific and shared differentiation antigens defined by monoclonal antibodiesGenetically engineered toxins in perspective.Toxin conjugate therapy of cancer.
P50
Q24634269-B4AFA8B5-D023-4548-AC1A-18045DA3E9C5Q28116193-FD039C55-8DCF-418E-A6DD-0207E85EA602Q28469210-F6195730-E660-489A-98E2-C50EBA075027Q32128259-5C71AE50-5953-4F5F-9F7F-2CB089DB467BQ33392660-60CC764B-CDF2-402E-833C-B30801951A9BQ33415505-FB630C05-A0F3-46D9-860E-45315B7A9F7DQ33485476-B240D763-EB98-4561-A925-5174E35FB0F1Q33590611-6647C1C3-9091-48FA-AFC4-999D733A69D1Q33725456-F2D22FD8-D6E7-4DE5-BF74-05962F13683BQ33762711-F3163749-652E-41AF-9E12-4E845EDE2F24Q33847816-53515F16-D0F8-4ED7-866D-D29219A48D30Q33907691-12ECFF11-A992-4670-99DA-0DEEA0D550BCQ33935031-86A5701B-C4F1-4B9F-9A54-14AE7FB7E2C1Q34098428-1ABD0CEC-A2B7-4553-9AE7-B20C9E0BFF49Q34129809-F10C8C4E-AAE5-4585-99AE-4E018AA1DF10Q34129989-BE1EAB6D-FCBE-4B3D-97DC-1CC0BA73495EQ34299266-DC80ED4D-0223-43EE-8BC3-FE35BF9FD8B0Q34352133-126D6B1A-EC51-4804-A21B-D096AE461750Q34445287-366D88E7-5C8B-4929-B79C-122BA84B3CE9Q34470462-FD3A1DD2-58AF-448F-81EF-4049E55E0549Q34556275-3C7383E1-F914-46B8-A2E9-9AF97A7374F8Q34762045-276ECBC6-D781-4700-8576-3DF66ED8732EQ34790763-DB3DA43E-1881-47A9-9813-B7C5A54BD7C6Q34939310-8CB3453D-DFA7-4A3B-A3AE-AD0EA9A91551Q34948022-042D3533-2DD4-4526-AEBE-3EB5ACD23C8DQ35031544-7335CC46-1A42-40B0-AF4B-C1CE591858C8Q35060905-3E72CF84-BC42-4FC7-9215-243B02A010DDQ35110411-832F5CD6-DD7B-4868-A8B6-299AC5581D6EQ35116184-9D1B7B10-E9BC-455C-8097-4B0C2D45F863Q35180101-B2904EBB-21A8-46FD-BFCA-50F3964081ADQ35206377-E8981C06-15F9-4217-A911-30F377471331Q35557067-70ED01F3-FF9F-440F-A813-9403F17A566EQ35636355-E48B25AB-5743-49FE-995E-37C752502DE0Q35669880-5213FE34-1FA2-4BEE-82DA-EEDC26E795F6Q35762225-DB9BDABA-A7BE-46D9-A7F3-38CFAC1C401FQ36086826-D870B358-A04F-4426-9693-0C7BFD543CCCQ36243031-B73F3291-DEEA-4F30-9597-70848EF209BBQ36280836-8F7C52CC-E7C8-4E08-A003-2F32290E095AQ36333244-31C52835-591A-4BF6-9152-8DBE8BA38320Q36336389-884ED5AD-EE20-46ED-8C7D-B003EAF506FF
P50
description
American oncologist and hematologist
@en
Amerikaans oncoloog
@nl
name
Arthur E. Frankel
@ast
Arthur E. Frankel
@en
Arthur E. Frankel
@es
Arthur E. Frankel
@ga
Arthur E. Frankel
@nl
Arthur E. Frankel
@sl
type
label
Arthur E. Frankel
@ast
Arthur E. Frankel
@en
Arthur E. Frankel
@es
Arthur E. Frankel
@ga
Arthur E. Frankel
@nl
Arthur E. Frankel
@sl
altLabel
A E Frankel
@en
A Frankel
@en
A. E. Frankel
@en
A. Frankel
@en
Art E Frankel
@en
Art E. Frankel
@en
Art Frankel
@en
Arthur E Frankel
@en
Arthur E. Frankel
@en
Arthur Edward Frankel
@en
prefLabel
Arthur E. Frankel
@ast
Arthur E. Frankel
@en
Arthur E. Frankel
@es
Arthur E. Frankel
@ga
Arthur E. Frankel
@nl
Arthur E. Frankel
@sl